Julia Haas
64Patents
16h-index
67Co-inventors
83Inventor score
Filing activity: Dec 15, 2004 → Jun 27, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8933084B2 | Macrocyclic compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 80 | Active |
| US8513263B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 77 | Active |
| US8791123B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 68 | Active |
| US8450322B2 | Substituted imidazo[1,2b]pyridazine compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 66 | Active |
| US8119592B2 | Compounds and methods for inhibiting hepatitis C viral replication | Chemistry; Metallurgy | 50 | Active |
| US8865698B2 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | Emerging Cross-Sectional Technologies | 43 | Active |
| US9493476B2 | Macrocyclic compounds as trk kinase inhibitors | Emerging Cross-Sectional Technologies | 43 | Active |
| US9127013B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Emerging Cross-Sectional Technologies | 40 | Active |
| US9682979B2 | Substituted pyrazolo [1,5-A] pyrimidine compounds as TRK kinase inhibitors | Emerging Cross-Sectional Technologies | 25 | Active |
| US9902741B2 | Macrocyclic compounds as TRK kinase inhibitors | Emerging Cross-Sectional Technologies | 22 | Active |
| US9718822B2 | Macrocyclic compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 22 | Active |
| US9676783B2 | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds | Emerging Cross-Sectional Technologies | 22 | Active |
| US9750744B2 | Macrocyclic compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 21 | Active |
| US9840519B2 | Macrocyclic compounds as TRK kinase inhibitors | Emerging Cross-Sectional Technologies | 21 | Active |
| US9447104B2 | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds | Emerging Cross-Sectional Technologies | 20 | Active |
| US9782415B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 19 | Active |
| US9796724B2 | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors | Emerging Cross-Sectional Technologies | 16 | Active |
| US9796723B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | Emerging Cross-Sectional Technologies | 15 | Active |
| US9795611B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | Emerging Cross-Sectional Technologies | 15 | Active |
| US10112942B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Chemistry; Metallurgy | 14 | Active |
| US9227975B2 | Method of treatment using substituted imidazo[1,2B]pyridazine compounds | Emerging Cross-Sectional Technologies | 12 | Active |
| US10174027B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Chemistry; Metallurgy | 12 | Active |
| US10138243B2 | Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors | Chemistry; Metallurgy | 10 | Active |
| US10174028B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | Chemistry; Metallurgy | 10 | Active |
| US10005783B2 | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds | Emerging Cross-Sectional Technologies | 9 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.